NEW YORK, Jan. 6, 2011 /PRNewswire/ -- Korn/Ferry International (NYSE: KFY), a premier global provider of talent management solutions, today announced that Paul Pospisil, Ph.D. has joined the Firm as a Senior Client Partner in the Biotechnology and Life Sciences Practice. He will be based out of the Firm's New York office.
Mr. Pospisil joins Korn/Ferry after serving more than 15 years as an investor and operating executive in the biotechnology industry. He brings to the Firm strong experience in drug discovery and development, finance, business development, technology assessment and evaluation, and business strategy.
Throughout his career, Mr. Pospisil has held senior-level positions at widely-regarded consulting and venture capital firms, as well as leading globally-focused biotechnology and bio-pharmaceutical organizations.
"Paul's unique credentials as both an investor and biotechnology executive, coupled with his vast knowledge of the issues and trends driving the industry, will be a great fit for our entrepreneurial life sciences clients," said Stephen Israel, Korn/Ferry's managing director, biotechnology and pharmaceuticals.
Mr. Pospisil joins the Firm from Aduro Capital LLC, an investment management company focused on the public healthcare sector and Aduro Partners LLC, an advisory firm focused on helping venture-backed and public life science companies assess, evaluate, partner opportunities and build businesses. Previously, he was a partner in life science investments at Atlas Venture and earlier was with Millennium Pharmaceuticals, where his last position was director, strategy leadership. Earlier, he was a new product manager at Altus Biologics, a spin-out of Vertex Pharmaceuticals.
Mr. Pospisil received a Ph.D. in Organic Chemistry from Harvard University and a Bachelor of Arts in Biochemistry from New York
|SOURCE Korn/Ferry International|
Copyright©2010 PR Newswire.
All rights reserved